1/28
Comprehensive vocabulary review flashcards covering endocrine pharmacology, antidiabetic agents, antidepressants, anxiolytics, antipsychotics, and antiparkinsonian drugs.
Selective Estrogen Receptor Modulators (SERMs)
A class of drugs with tissue-specific estrogen agonist or antagonist activity; examples include ospemifene (Osphena) for vaginal dryness, tamoxifen for hormone-sensitive breast cancer, and raloxifene for osteoporosis.
Clomiphene (Clomid)
A synthetic nonsteroidal estrogen receptor antagonist that stimulates ovulation by blocking the negative feedback of estradiol on LH and FSH secretion, which carries an increased chance of twinning.
Phosphodiesterase Type 5 (PDE5) Inhibitors
Vasodilating agents, including sildenafil (Viagra) and tadalafil (Cialis), that treat erectile dysfunction by preventing the enzymatic degradation of cGMP, thereby maintaining smooth muscle relaxation and penile erection.

Pancreatic Beta-Cell Insulin Secretion Mechanism
A physiological cascade wherein glucose enters via GLUT2, undergoes metabolism to generate ATP, closes ATP-sensitive K+ channels (SUR), depolarizes the plasma membrane, opens voltage-gated Ca2+ channels, and triggers the exocytosis of insulin and amylin.

Insulin Analogs
Recombinant human insulin molecules engineered with amino acid modifications (at positions 1, 3, 28, 29 on the B chain or 21 on the A chain) to alter kinetics, yielding rapid-acting agents (lispro, aspart, glulisine) or prolonged, basal-release agents (detemir, glargine).
Sulfonylureas
Oral secretagogue antidiabetic drugs (second-generation agents include glipizide, glimepiride, and glyburide) that stimulate insulin release by binding to sulfonylurea receptors (SUR) and closing ATP-dependent K+ channels on pancreatic beta cells.
Metformin (Glucophage)
A biguanide antihyperglycemic drug that suppresses hepatic glucose production and decreases intestinal glucose absorption; it does not cause hypoglycemia but carries a rare, potentially fatal risk of lactic acidosis.
SGLT2 Inhibitors
Antidiabetic drugs, including canagliflozin (Invokana) and dapagliflozin (Farxiga), that inhibit sodium-glucose cotransporter 2 in the kidneys to block glucose reabsorption, with common side effects of urinary tract infections, yeast infections, and dehydration.
DPP-4 Inhibitors
Antihyperglycemic medications such as alogliptin (Nesina) and saxagliptin (Onglyza) that inhibit dipeptidyl peptidase-4, extending the half-life of endogenous GLP-1 incretins to augment glucose-dependent insulin secretion.
Pramlintide (Symlin)
A synthetic amylin analog administered subcutaneously at mealtime alongside insulin in Type 1 and Type 2 diabetes that slows glucose absorption and promotes central satiety.
5-HT3 Receptor
A ligand-gated cation channel subtype of the serotonin receptor family whose activation induces nausea, vomiting, and neuronal excitation.
Serotonin Syndrome
A dangerous toxic state resulting from excessive CNS serotonin levels, presenting clinically with confusion, restlessness, tremors, hyperthermia (fever), coma, and death.
Tricyclic Antidepressants (TCAs)
Antidepressant agents (including secondary amines like desipramine and tertiary amines like amitriptyline) that block the reuptake of norepinephrine and serotonin while producing prominent sedation, anticholinergic effects, antihistaminic actions, and alpha-adrenergic blockade.
Monoamine Oxidase Inhibitors (MAOIs)
Antidepressants such as phenelzine (Nardil), tranylcypromine (Parnate), and isocarboxazid (Marplan) that require strict dietary avoidance of tyramine-containing foods (aged cheeses, wine, beer) and decongestants to avoid life-threatening hypertensive crisis.
Bupropion (Wellbutrin)
A norepinephrine and dopamine reuptake inhibitor (NDRI) that enhances the release and inhibits the reuptake of NE and DA without causing sexual dysfunction; notable adverse effects include agitation, anorexia, and increased libido.
Lithium
A monovalent cation mood stabilizer that shares chemical properties with sodium and dampens neuronal conduction and excitability in bipolar disorder and acute mania; it carries cardiac and renal toxicity and is contraindicated in thyroid conditions.

GABAA Receptor Complex
A pentameric ligand-gated chloride channel composed of α, β, and γ subunits that hyperpolarizes neuronal membranes when bound by GABA; it possesses allosteric modulating sites for benzodiazepines and flumazenil.
Buspirone (BuSpar)
A non-benzodiazepine anxiolytic that acts as a partial agonist at serotonin receptors, providing antianxiety effects without inducing significant sedation, hypnosis, anticonvulsant activity, or skeletal muscle relaxation.
Extrapyramidal Symptoms (EPS)
Motor abnormalities resembling Parkinson's disease—such as dystonic reactions, akathisia, muscle rigidity, and resting tremor—caused by excessive blockade of dopamine D2 receptors in the basal ganglia by antipsychotic medications.
Haloperidol (Haldol)
A high-potency butyrophenone first-generation antipsychotic with potent D2 receptor antagonism that carries a low incidence of sedation and anticholinergic effects but a very high risk of extrapyramidal symptoms (EPS).
Clozapine (Clozaril)
An atypical antipsychotic of moderate potency with very low EPS risk, but associated with serious adverse effects including agranulocytosis (requiring blood monitoring), seizures, weight gain, prominent sedation, and postural hypotension.

SMART (Parkinson's Disease Signs)
A clinical mnemonic capturing the hallmark motor signs of Parkinson's disease: Shuffling gait, Mask-like face, Akinesia, Rigidity, and Tremor.

Basal Ganglia Neurotransmitter Balance
A physiological balance model where normal motor behavior requires balanced dopamine (DA) and acetylcholine (ACh) signaling; Parkinson's disease reflects low DA and relatively excessive ACh, whereas Huntington's chorea and Tourette's reflect high DA and low ACh.

Carbidopa (Lodosyn)
A peripheral DOPA decarboxylase inhibitor co-administered with levodopa (as Sinemet) that prevents the peripheral breakdown of L-DOPA into dopamine, drastically increasing L-DOPA brain penetration from 1–3% to 10% while curbing peripheral toxicities like nausea.
Tolcapone (Tasmar)
A catechol-O-methyltransferase (COMT) inhibitor that acts both peripherally and centrally across the blood-brain barrier to reduce the degradation of levodopa and dopamine, though clinically restricted by liver toxicity risk.
Entacapone (Comtan)
A COMT inhibitor that selectively acts in peripheral tissues to prevent the conversion of L-DOPA to 3-O-methyldopa (3-OMD), prolonging L-DOPA's duration of action.
Selegiline (Eldepryl)
An irreversible monoamine oxidase-B (MAO-B) inhibitor that selectively blocks dopamine metabolism within the brain, thereby elevating central dopamine concentrations in Parkinson's disease.

Livedo Reticularis
A purplish, lace-like mottled vascular skin discoloration primarily affecting the lower extremities, known as a characteristic benign dermatological side effect of amantadine therapy.
Benztropine (Cogentin)
A centrally acting anticholinergic drug used in Parkinson's disease to suppress excessive striatal cholinergic neurotransmission and to treat drug-induced extrapyramidal symptoms in patients taking antipsychotics.